Acurx Pharmaceuticals (ACXP)
(Delayed Data from NSDQ)
$2.20 USD
-0.01 (-0.45%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $2.21 +0.01 (0.45%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ACXP 2.20 -0.01(-0.45%)
Will ACXP be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ACXP based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ACXP
ACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment Conference
Acurx Pharmaceuticals’ Ibezapolstat: A Strong Buy Ahead of Phase 3 for CDI Treatment
Ibezapolstat’s Strategic Advancements and Market Potential Bolster Buy Rating for Acurx Pharmaceuticals
ACXP Stock Earnings: Acurx Pharmaceuticals Misses EPS for Q2 2024
Acurx Pharmaceuticals, Inc. (ACXP) Q2 2024 Earnings Call Transcript